ANIP Share Price Performance
US$73.31
6.98 (10.52%)
33.7% undervalued intrinsic discount
US$110.50
Fair Value
Price US$73.31
AnalystConsensusTarget US$110.50
AnalystLowTarget US$90.00
AnalystHighTarget US$120.00
Fair ValueUS$110.63
Share Pricen/a
ANI Pharmaceuticals, Inc. Stock Price
- 3 Narratives written by author
- 1 Comments on narratives written by author
- 10 Fair Values set on narratives written by author
ANIP Community Narratives
AN
Fair Value US$110.63 33.7% undervalued intrinsic discount
Expanding ACTH Potential And Rare Disease Markets Will Evolve
0users have liked this narrative
1users have commented on this narrative
4users have followed this narrative
AN
Fair Value US$90 18.5% undervalued intrinsic discount
Pharmaceutical Pricing Pressures Will Erode Margins Amid Tighter Controls
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$120 38.9% undervalued intrinsic discount
Emerging Markets And Aging Populations Will Expand Patient Access
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Expanding ACTH Potential And Rare Disease Markets Will Evolve
Key Takeaways Multiyear revenue growth is driven by expanding Cortrophin Gel potential, new product launches, and increasing adoption among previously untapped prescribers. Strategic investments in U.S. manufacturing, rare diseases, and complex generics strengthen margins, diversify the portfolio, and support resilience against supply chain and regulatory risks.Read more
143
users have viewed this narrative0users have liked this narrative
1users have commented on this narrative
4users have followed this narrative
AN
US$110.63
33.7% undervalued intrinsic discount
Fair Value
Revenue
14.56% p.a.
Profit Margin
14.43%
Future PE
16.25x
Price in 2029
US$131.52
Pharmaceutical Pricing Pressures Will Erode Margins Amid Tighter Controls
Key Takeaways Reliance on a few specialty products and a thin pipeline leaves earnings highly vulnerable to pricing, regulatory, and competitive pressures. Rising compliance costs, regulatory demands, and payer restrictions threaten profitability and limit the company's long-term growth potential.Read more
24
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$90
18.5% undervalued intrinsic discount
Fair Value
Revenue
11.07% p.a.
Profit Margin
16.39%
Future PE
12.77x
Price in 2029
US$107
Emerging Markets And Aging Populations Will Expand Patient Access
Key Takeaways Strong momentum in rare disease and retina drug franchises, plus manufacturing efficiency, is fueling outsized revenue growth and expanding margins via product and market diversification. Domestic manufacturing focus and strategic acquisitions enhance supply chain resiliency and position ANI to capitalize on industry patent cliffs and emerging healthcare trends.Read more
12
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$120
38.9% undervalued intrinsic discount
Fair Value
Profit Margin
8.45%
Future PE
30.83x
Price in 2028
US$140.04
Trending Discussion
Recently Updated Narratives
AN
ANIP: Higher 2026 Guidance And Margin Outlook Will Support Stronger Earnings Power
Fair Value: US$110.63 33.7% undervalued intrinsic discount
4 followersusers have followed this narrative
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
ANIP: Higher 2026 Guidance Will Test Assumed Margin Expansion
Fair Value: US$90 18.5% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Emerging Markets And Aging Populations Will Expand Patient Access
Fair Value: US$120 38.9% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
ANI Pharmaceuticals, Inc. Key Details
About ANIP
- Founded
- 2001
- Employees
- 970
- CEO
- WebsiteView website
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
